Early Signal

Early Signal is a digital health and analytics company focused on developing personalized monitoring solutions for patients with central nervous system (CNS) disorders and rare diseases. The company utilizes wearable sensors and advanced machine learning algorithms to capture and analyze high-frequency physiological and behavioral data, creating "digital biomarkers" that provide objective measures of disease progression. Their platform aims to improve the sensitivity of clinical trials and enhance patient care by identifying subtle changes in health that traditional clinical assessments might miss. In 2019, Early Signal was acquired by Teva Pharmaceutical Industries to integrate its predictive analytics and remote monitoring capabilities into Teva's digital health portfolio.